Хуудас 1 -аас 41 үр дүн
TECHNICAL FIELD
The present invention relates to a lactic acid bacterium-containing composition in which a lactic acid bacterium has a human papilloma virus (HPV) E7 protein-derived polypeptide on a surface thereof a therapeutic oral pharmaceutical composition for at least one of an HPV infectious
CROSS-REFERENCES TO RELATED APPLICATIONS
None
FEDERALLY FUNDED RESEARCH
None
BACKGROUND OF THE INVENTION
Discovery of a new chemical reaction, a fundamental property of nature, is a major finding. For example, without the discovery of the Haber process, which resulted in nitrogen fixation, modern
INCORPORATION OF SEQUENCE LISTING
Two paper copies of the sequence listing (Sequence Listing No. 1 and Sequence Listing No. 2) and a computer-readable form of the sequence listing on 3.5 floppy disk containing the file named Sequence Listing.txt, as modified on Apr. 6, 2005, are herein incorporated
Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
In
Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
In
TECHNICAL FIELD
This invention relates to a composition containing bacteria. More particularly, it relates to a composition or pharmaceutical composition for human or animals which comprises as an active ingredient bacteria or processed product thereof capable of converting lactic acid into butyric
FIELD OF THE INVENTION
The present invention relates to a lactic acid bacterium, useful as a therapeutic agent for a disease that is in an anaerobic environment such as a solid tumor, the lactic acid bacterium has been mutated from being facultatively anaerobic to being obligately anaerobic, a
TECHNICAL FIELD OF THE INVENTION
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds,
TECHNICAL FIELD OF THE INVENTION
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds,
TECHNICAL FIELD OF THE INVENTION
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds,
The present invention relates to a pharmaceutical composition comprising a somatostatin analogue, and to its use in the treatment of breast cancer.
Somatostatin is a tetradecapeptide incorporating a cyclic dodecapeptide having the structure: ##STR1## and has the properties of inhibiting the release
The present invention relates to a pharmaceutical composition comprising a somatostatin analogue, and to its use in the treatment of breast cancer.
Somatostatin is a tetradecapeptide incorporating a cyclic dodecapeptide having the structure: ##STR1## and has the properties of inhibiting the release
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a use or method of preventing and/or treating diseases in subjects by administering a fermented soy extract, FSE, to the subjects in need of the prevention and/or treatment of the diseases. The fermented soy extract is
This is the U.S. national phase of International Application No. PCT/IB2014/067057, filed Dec. 18, 2014, which designated the U.S. and claims priority to Italian Application No. RM2013A000700, filed Dec. 19, 2013; the entire contents of each of which are hereby incorporated by reference.
FIELD OF
TECHNICAL FIELD OF THE INVENTION
This invention relates to the use of butyrate prodrugs derived from lactic acid for treating inflammatory bowel disease. The invention also relates to the use of those prodrugs for the treatment of a chemotherapy-induced mucocutaneous side effect in a patient. The